Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006133 · ClinicalTrials.gov registry record · NA
Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus
A NA study, sponsored by National Center for Research Resources (NCRR).
- Completed
- Registry status
- NA
- Development phase
- 970
- Enrollment target
NCT00006133: Completed NA study, sponsored by National Center for Research Resources (NCRR).
NCT00006133 is a NA study that has completed, run by National Center for Research Resources (NCRR). The registered enrollment target is 970 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006133, a NA study, has completed, sponsored by National Center for Research Resources (NCRR).
- COMPLETED
- Registry status
- NA
- Development phase
- 970 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Determine the effect of oral contraceptives containing low-dose synthetic estrogens and progestins on disease activity in premenopausal women with inactive, stable, or moderate systemic lupus erythematosus (SLE). II. Determine the effect of hormone replacement therapy with conjugated estrogens and progestins on disease activity in postmenopausal women with inactive, stable, or moderate SLE.
Interventions
- DRUG medroxyprogesterone
- DRUG ethinyl estradiol
- DRUG estradiol
- DRUG norethindrone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 970 participants |
| Start Date | 2000-06 |
| Phase | NA |
What the finished NCT00006133 record still lists
NCT00006133 is an interventional study that assigns participants to a tested intervention. The registered 970 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 4 interventions - of which medroxyprogesterone is the first listed.
NCT00006133 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006133 about?
NCT00006133 is a clinical study titled "Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus". OBJECTIVES: I. Determine the effect of oral contraceptives containing low-dose synthetic estrogens and progestins on disease activity in premenopausal women with inactive, stable, or moderate systemic lupus erythematosus (SLE). II. Determine the effect of hormone replacement therapy with conjugated...
What is the current status of trial NCT00006133?
This trial is currently completed. It is a NA study. The enrollment target is 970 participants. The study started on 2000-06.
What interventions are being tested in trial NCT00006133?
The interventions under investigation include: medroxyprogesterone (DRUG), ethinyl estradiol (DRUG), estradiol (DRUG), norethindrone (DRUG).
Who is sponsoring clinical trial NCT00006133?
This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00006133's enrollment target sits among peer trials
970 123rd of 2000 higher than 1,878 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05354141 · 970 participants · Phase 3
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia